Agency News
'Why buy a network that even Dentsu couldn’t fix?': Inside the gamble of Dentsu's international arm sale
Patanjali misleading ads case: Kerala court summons Baba Ramdev and Acharya Balkrishna
A Kerala Court has directed Patanjali Ayurved Co-founder Baba Ramdev and its Managing Director Acharya Balkrishna to appear before it on June 03, 2024 in a case of publishing misleading advertisements in English and Malayalam newspapers.
Baba Ramdev and Acharya Balkrishna approached the court to quash the proceedings against them where one of their argument was based on the violation of the limitation period, stated a Bar and Bench report.
Yoga guru Baba Ramdev and his associate Acharya Balkrishna have been asked to appear before the Judicial First Class Magistrate Court in Kozhikode on June 3 in a case related to placing misleading advertisements in English and Malayalam newspapers. Both are founders of Haridwar-based Divya Pharmacy that markets Patanjali Ayurved’s products; Acharya Balkrishna is also its Managing Director.
This comes after the Drugs Inspector, Office of the Assistant Drugs Controller, Kozhikode filed a complaint in Kozhikode Court against Divya Pharmacy. The case has been filed under Section 3 of The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. Section 3 prohibits the advertisement of certain drugs for the treatment of certain diseases and disorders.
The specific allegation was misleading advertisements were published claiming that “Divya Lipdom” tablet manufactured by Divya Pharmacy claimed to reduce abnormal levels of cholesterol and fat in the body and to improve fat metabolism. And, the product “Nutrella Diabetic Care” manufactured by Patanjali Ayurved claims to manage blood sugar levels and body weight.
Baba Ramdev’s Patanjali has been under scrutiny for issuing misleading advertisements for health cures. Last month, the Supreme Court lambasted both Ramdev and Acharya Balkrishna of Patanjali for advertisements that promoted the Ayush treatment system while undermining modern, evidence-based medicine and asked them to tender a public apology.
After issuing the apology, the duo later asked the SC for time to file affidavit regarding steps taken to recall advertisement for medicines for which the company’s license was revoked. The SC granted them a period of three weeks.
SPOTLIGHT
Today’s B2B marketers wear many hats: strategist, technologist, and storyteller.
Read MoreExplained: What the Online Gaming Bill means for the industry, users and platforms
The Online Gaming Bill 2025 imposes severe penalties, allows warrantless search and seizure, and empowers a central authority to regulate the digital gaming ecosystem. It is expected to disrupt platforms, payment systems, and advertising in the sector. Here's all you need to know about the bill.